To date, we have constructed a library of 6 Xycrobes that we are currently testing in several human skin models with our partner company Johnson & Johnson. We have an agreement with J&J signed in October of 2016 where they are evaluating our technology for possible licensing at the end of 2017.
Microbes are everywhere. They live around us, on us and even in us. Xycrobe Therapeutics is developing innovations that take advantage of the ubiquitous nature of these microbes by turning them into SUPERHERO bacteria that fight off skin conditions like acne, psoriasis and dermatitis. While we won't have our therapeutic Xycrobes available for a few years (FDA), we hope to offer Cosmetic Xycrobes in the near future. These are like the sidekick version of the Superhero bacteria, and they can really help to improve the appearance of skin, even in those without skin conditions. Some of the things we have seen in pilot study are:
•Significantly reduced Staph (e.g., MRSA)
–Targeted anti-microbial peptides kill only the “bad” bacteria and keep the "good" bacteria going strong
•Near elimination of blackheads
–Natural Production of antioxidants, as strong as Vit C or Vit E are released throughout the day!
•Reduced pore size and appearance
–Xycrobes eat the sebaceous and oil secretions of your pores, reducing the contents and helping to shrink the pore
•Smoothing of skin texture
–Xycrobes are anti-inflammatory
•No adverse reactions!
–Xycrobes’ don't grow unless you want them to (by adding more Xycrobe serum) so you don't have to worry about overgrowth, infection, transfering to another person (which would be fine), etc!
So, are you ready to Join the Xycrobe Revolution in skincare?!
The Market opportunity represented in the inflammatory skin space (acne, psoriasis, dermatities) can be defined by the total affected demographic for each disease and the corresponding dollar amount spent yearly in pursuit of treatment. According to JAAD (January 2008 Volume 58, Issue 1, Pages 56–59), acne affects upwards of 79+ Million people in the United States alone (104 Million globally), with over 40 million of those between the ages of 20 and 40 years old. According the The British Journal of Dermatology, the costs associated with the treatment of acne exceed $3 billion in the US alone (2013;168:474-85). Psoriasis affects 8 million Americans (125 Million globally) and costs it's sufferers around $5 Billion in the US alone. Dermatitis also affects about 8 Million Americans (133 Million globally) and costs its sufferers around $1.5 Billion in the US alone.
Projected 3 Year Growth
As we are still in pre-clinical development, our revenue from our therapeutic technologies will likely be more than 3 years out due to the timeline required for clinical testing and FDA approval. However, we are also developing a "Xycrobe Lite" technology that we are aiming to register as a cosmetic, and this could potentially be a viable product within a year depending on when we recieve funding and if we end up partnering with J&J for codevelopment. If Xycrobe was to not take on a commercial partner, we calculate that we could generate roughly $5 Million for every 10,000 consumers that adopt the Xycrobe cosmetic product(s).
Along with our development of therapeutic Xycrobes for Skin Disease, we plan to roll out a "cosmetic" Xycrobe product (30 individually packaged doses of live xycrobes per box) along with "Microbe friendly" adjunct products like moisturizer and sunscreen to be used with Xycrobes. The initial Live Xycrobe product will cost pennies per dose to produce and package, making production costs (not including capital equipment needed initially) less than $2 per box. As these technologies sell for any where from $20 to $300 per month suply (depending on distribution route), we are confident that we can achieve high margins regardless of which method of sales and pricepoint we adopt (i.e. brick and morter vs. ecommerce).
There are several small companies that are in development of microbe-utilizing technologies for the dermatology space. The only of these companies that is currently on the market with a true "probiotic" type solution is Aobiome. While they are paving the way for other microbiome skin solutions, Xycrobe is the only of these companies that 1) Addresses both the bacteria and genetic issues that affect acne patients and 2) has biocontainment built into the technology so that we can control dosing and prevent any potential infection from occuring (even good bacteria can cause infections at times).
We are currently starting a small pilot study of our cosmetic product (live Xycrobes, non-therapeutic strains). We antiicipate to have data on this sometimes in July.
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.